The link to the online publication can be found here. The PAX-D study results guided Alto’s acquisition of ALTO-207, a fixed-dose combination of pramipexole and the antiemetic, ondansetron.

Scale AI announced a "significant" new investment by Meta late Thursday that values the startup at more than $29 billion and puts its founder to work for the tech titan.Scale AI founder and chief ...

Meta was reportedly pouring more than US$10 billion into San Francisco-based Scale AI. Read more at straitstimes.com. Read more at straitstimes.com.

Pittsburgh Steelers is all-in after trading for DK Metcalf and pairing him with Aaron Rodgers, mirroring the Philadelphia Eagles' A.J. Brown gamble that sparked a Super Bowl run. Can lightning ...

Meta Invests $14.3 Billion in Scale AI to Kick-Start Superintelligence Lab Meta is making its first major minority investment in an outside company as it tries to catch up to a growing field of ...

Steelers Making Major Bet on D.K. Trade With Bold Blueprint Goal originally appeared on Athlon Sports. When the Pittsburgh Steelers sent a second-round pick to the Seattle Seahawks for DK Metcalf ...

Scale AI announced a "significant" new investment by Meta late Thursday that values the startup at more than $29 billion and puts its founder to work for the tech titan.Scale AI founder and chief ...

Alto Neuroscience, Inc. a clinical-stage biopharmaceutical company focused on the development of novel precision medicines for neuropsychiatric disorders, today highlighted The Lancet Psychiatry ...

Furthermore, Alto reported progress in its trials for ALTO-300, a drug for major depressive disorder (MDD), showing a favorable tolerability profile in recent studies.

Factbox-Meta’s Scale AI stake buyout spotlights other major deals amid regulatory risks Stock Markets Published 06/12/2025, 11:29 PM Updated 06/13/2025, 12:18 AM ...

Alto Neuroscience Highlights Peer-Reviewed Publication of PAX-D Study in The Lancet Psychiatry Demonstrating Robust Clinical Effects of Pramipexole for Patients with Treatment-Resistant Depression ...

MOUNTAIN VIEW, Calif., June 30, 2025--Alto Neuroscience, Inc. ("Alto") (NYSE: ANRO) a clinical-stage biopharmaceutical company focused on the development of novel precision medicines for ...